| Bronvermelding: | -Hiemke et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. pharmacospychiatry 44:195-235
-Winter H R , Earley W R , Hamer-Maansson J E et al. Steady-state pharmacokinetic, safety, and tolerability profi les of quetiapine, Norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders . J Child Adolesc Psychopharmacol 2008 ; 18 : 81 – 98
-Vernaleken I , Janouschek H , Raptis M et al. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas . Int J Neuropsychopharmacol 2010 ; 13 : 951 – 960
-Stieff enhofer V , Saglam H , Schmidtmann I et al. Clozapine plasma level monitoring for prediction of rehospitalization schizophrenic outpatients. Pharmacopsychiatry 2011 ; 44 : 55 – 59
-Small J G , Hirsch S R , Arvanitis L A et al. Quetiapine in patients with schizophrenia – a high- and low-dose double-blind comparison with placebo.
-Parker D R , McIntyre I M . Case studies of post-mortem quetiapine: therapeutic or toxic concentrations? J Analyt Toxicol 2005 ; 29 :407 – 412
-Hasselstrøm J , Linnet K . Quetiapine serum concentrations in psychiatric patients: the infl uence of comedication . Ther Drug Monit 2004 ; 26 : 486 – 491
-Gerlach M , Hünnerkopf R , Rothenhöfer S et al. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders . Pharmacopsychiatry 2007 ; 40 : 72 – 76
-Figueroa C , Brecher M , Hamer-Maansson J E et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release . Prog Neuropsychopharmacol Biol Psychiatry 2009 ; 33 : 199 – 204
-Castberg I , Skogvoll E , Spigset O . Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service . J Clin Psychiatry 2007 ; 68 : 1540 – 1545
|
